about
Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level.Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseasesStructure-guided development of heterodimer-selective GPCR ligandsToward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers.Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects.Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.Pharmacological characterization of tachykinin tetrabranched derivatives.Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.Combining rimonabant and fentanyl in a single entity: preparation and pharmacological resultsStructure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties.Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.Effect of linker length and composition on heterobivalent ligand-mediated receptor cross-talk between the A1 adenosine and β2 adrenergic receptors.Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.Description of a bivalent cannabinoid ligand with hypophagic properties.Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo.Dopamine D2 receptors dimers: how can we pharmacologically target them?Optimizing divalent inhibitors of Pseudomonas aeruginosa lectin LecA by using a rigid spacer.Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M2R Affinity and Selectivity.
P2860
Q27348715-0AEEEE2A-C730-4B7A-96F8-1FDE6DE160DCQ28083987-F4B17C68-54A9-434B-914C-B007EDDC3C96Q28828634-5525ADD4-0852-4F3D-95B8-B4536C4C7C4DQ33768567-5D7D2F4E-B0C6-4E58-B62D-AA8B156640F5Q34145241-35170B88-2073-4707-9B03-5E7396F71A22Q34410429-A26E8523-237E-407B-BA17-A024ABA4BB41Q34571425-F60CC73A-54DF-493D-9D78-B70AA5E458AEQ35031314-DA1F3777-CFA4-40EA-967F-3EF8828384E2Q35216669-1C29F5BD-863B-48F1-95F2-6031BDA21F01Q37602963-B21E23F3-41C5-4103-B960-4549FD28DC42Q37739812-59F50B51-A4F2-4D46-A37E-EFDE395D7C29Q38066121-724AA3EB-2B3E-4B97-8066-ED57659F7C7EQ38395251-B261A889-80A7-4582-A71D-CB86CD79DFA3Q38458891-444D1837-A8BC-49EB-BBBC-0DB835B0CCE4Q38846984-DFB9D441-CDC0-46C4-8EF5-46CDEC95294DQ39084286-805A46CF-20B4-4275-B2FC-8B7F4090BC6EQ41411764-03BBD5E9-E9CA-4F73-9F11-28C4D8BD3E07Q43075623-AC3D2BCD-9B69-412E-9D25-EC3FC0A4180EQ45840317-FBD04FBD-C7C3-4792-A5DE-31122C33EB0DQ48351742-BEC6ADA6-E4B7-4470-B168-DD22AB5CB187Q50994126-F11A8AD1-9CEE-48D8-85C7-41EE085F8B7BQ54488283-BD3BFFF0-3ACF-47FB-A30D-8D175FCBB9C9Q55710562-0E14FB33-8A02-4C92-B8D3-39AE7B5661E0
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Design strategies for bivalent ligands targeting GPCRs.
@ast
Design strategies for bivalent ligands targeting GPCRs.
@en
Design strategies for bivalent ligands targeting GPCRs.
@nl
type
label
Design strategies for bivalent ligands targeting GPCRs.
@ast
Design strategies for bivalent ligands targeting GPCRs.
@en
Design strategies for bivalent ligands targeting GPCRs.
@nl
prefLabel
Design strategies for bivalent ligands targeting GPCRs.
@ast
Design strategies for bivalent ligands targeting GPCRs.
@en
Design strategies for bivalent ligands targeting GPCRs.
@nl
P2860
P356
P1433
P1476
Design strategies for bivalent ligands targeting GPCRs.
@en
P2093
Ben Capuano
P2860
P304
P356
10.1002/CMDC.201100101
P577
2011-04-21T00:00:00Z